Description
Product details
PIRFENOID 400 is a pharmaceutical formulation containing Pirfenidone 400mg as its active ingredient. This medication represents a significant advancement in the treatment of idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scarring of lung tissue. PIRFENOID 400 belongs to a class of medications known as antifibrotic agents, designed to slow the progression of lung fibrosis and help patients maintain their quality of life. Idiopathic pulmonary fibrosis is a chronic, progressive condition where the lung tissue becomes thick and stiff over time, making it increasingly difficult for patients to breathe. PIRFENOID 400 works at the cellular level to address this scarring process, offering hope to those diagnosed with this challenging condition. Understanding How PIRFENOID 400 Works The active ingredient in PIRFENOID 400, Pirfenidone, operates through multiple mechanisms to combat pulmonary fibrosis. While the exact mechanism is not completely understood, research suggests that Pirfenidone exhibits both antifibrotic and anti-inflammatory properties. It works by reducing the production of growth factors and procollagens, which are substances involved in the formation of scar tissue in the lungs. By interfering with the fibrotic process, PIRFENOID 400 helps slow down the rate at which lung tissue becomes scarred and damaged. This intervention is crucial because once lung tissue becomes severely scarred, the damage is generally irreversible. The medication doesn't cure IPF, but it can significantly slow its progression, allowing patients to maintain better lung function for longer periods. Primary Uses and Indications PIRFENOID 400 is primarily prescribed for the treatment of mild to moderate idiopathic pulmonary fibrosis. Healthcare providers recommend this medication for patients who have been diagnosed with IPF through comprehensive testing, including high-resolution CT scans, pulmonary function tests, and sometimes lung biopsies. The medication is most effective when started early in the disease process, before extensive lung damage has occurred. It is intended for long-term use as part of a comprehensive treatment plan that may also include pulmonary rehabilitation, oxygen therapy, and other supportive measures. Key Benefits of PIRFENOID 400 Slowing Disease Progression The most significant benefit of PIRFENOID 400 is its ability to slow the progression of idiopathic pulmonary fibrosis. Clinical studies have demonstrated that patients taking Pirfenidone experience a reduced decline in lung function compared to those not receiving treatment. This means patients can maintain their breathing capacity and overall lung health for extended periods. Improved Quality of Life By slowing disease progression, PIRFENOID 400 helps patients maintain their ability to perform daily activities. Patients often report being able to continue working, engaging in social activities, and maintaining independence longer than they might without treatment. This preservation of quality of life is invaluable for both patients and their families. Reduced Risk of Acute Exacerbations Research indicates that PIRFENOID 400 may help reduce the risk of acute exacerbations of IPF, which are sudden worsening episodes that can be life-threatening. By stabilizing the disease, the medication provides patients with more predictable disease management and fewer emergency situations. Extended Survival Rates Studies have shown that treatment with Pirfenidone may be associated with improved survival rates in IPF patients. While IPF remains a serious condition, PIRFENOID 400 offers patients additional time and better overall outcomes. Well-Established Safety Profile PIRFENOID 400 has been extensively studied in clinical trials involving thousands of patients worldwide. This extensive research has established a well-understood safety profile, allowing healthcare providers to effectively manage and monitor patients on this therapy. Dosage and Administration PIRFENOID 400 is typically administered orally with food to reduce the likelihood of gastrointestinal side effects. The usual recommended dosage involves a gradual titration period where the dose is slowly increased over the initial weeks of treatment to help the body adjust to the medication. Patients should always follow their healthcare provider's specific dosing instructions and never adjust their dose without medical guidance. Potential Side Effects Like all medications, PIRFENOID 400 can cause side effects, though not everyone experiences them. Understanding these potential effects helps patients and healthcare providers monitor treatment effectively. Common Side Effects The most frequently reported side effects include nausea, loss of appetite, stomach upset, diarrhea, and indigestion. These gastrointestinal effects are often most noticeable when starting treatment but may improve over time. Taking the medication with food can help minimize these symptoms. Skin-related side effects are also common, including photosensitivity (increased sensitivity to sunlight), rash, and dry skin. Patients taking PIRFENOID 400 should use broad-spectrum sunscreen and protective clothing when exposed to sunlight. Fatigue and dizziness are reported by some patients, particularly during the initial treatment period. These effects may impact daily activities and should be discussed with a healthcare provider if they persist or worsen. Less Common but Serious Side Effects Elevated liver enzymes have been observed in some patients taking Pirfenidone, which is why regular liver function monitoring is essential during treatment. Most cases are mild and reversible with dose adjustment or temporary discontinuation. Some patients may experience significant weight loss, which requires nutritional monitoring and support. Rare cases of angioedema (severe swelling) and severe allergic reactions have been reported and require immediate medical attention. Managing Side Effects Most side effects can be effectively managed through dose adjustments, symptomatic treatment, or temporary interruption of therapy. Open communication with healthcare providers is essential for optimizing treatment while minimizing adverse effects. Important Precautions and Monitoring Patients taking PIRFENOID 400 require regular monitoring, including liver function tests, typically performed monthly for the first six months and then periodically thereafter. Sun protection measures are crucial, including use of SPF 50+ sunscreen, protective clothing, and avoiding peak sun hours. Women of childbearing potential should use effective contraception, as the safety of Pirfenidone during pregnancy has not been established. Patients should inform their healthcare provider of all other medications they are taking, as drug interactions may occur. Smoking can reduce the effectiveness of PIRFENOID 400, and patients are strongly encouraged to quit smoking as part of their comprehensive IPF management strategy. Conclusion PIRFENOID 400 represents a valuable therapeutic option for patients diagnosed with idiopathic pulmonary fibrosis. By slowing disease progression, reducing the decline in lung function, and potentially improving survival outcomes, this medication offers meaningful benefits to those facing this challenging condition. While side effects can occur, they are generally manageable with appropriate monitoring and medical support.
